Corbus Pharmaceuticals Holdings, Inc.
CRBP
$8.83
-$0.22-2.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 18.41M | 20.86M | 15.19M | 15.64M | 8.79M |
| Gross Profit | -18.41M | -20.86M | -15.19M | -15.64M | -8.79M |
| SG&A Expenses | 3.56M | 3.56M | 3.97M | 4.13M | 3.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -1.12M | -- |
| Total Operating Expenses | 21.97M | 24.42M | 19.15M | 18.66M | 12.61M |
| Operating Income | -21.97M | -24.42M | -19.15M | -18.66M | -12.61M |
| Income Before Tax | -20.56M | -23.34M | -17.66M | -16.98M | -9.53M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.56M | -23.34M | -17.66M | -16.98M | -9.53M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.56M | -23.34M | -17.66M | -16.98M | -9.53M |
| EBIT | -21.97M | -24.42M | -19.15M | -18.66M | -12.61M |
| EBITDA | -21.92M | -24.37M | -19.10M | -18.58M | -12.47M |
| EPS Basic | -1.24 | -1.90 | -1.44 | -1.39 | -0.78 |
| Normalized Basic EPS | -0.82 | -1.19 | -0.90 | -0.87 | -0.69 |
| EPS Diluted | -1.24 | -1.90 | -1.44 | -1.39 | -0.78 |
| Normalized Diluted EPS | -0.82 | -1.19 | -0.90 | -0.87 | -0.69 |
| Average Basic Shares Outstanding | 16.52M | 12.31M | 12.24M | 12.20M | 12.18M |
| Average Diluted Shares Outstanding | 16.52M | 12.31M | 12.24M | 12.20M | 12.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |